

COURSE FACULTY, IAS–USA STAFF, AND BOARD OF DIRECTORS

FINANCIAL RELATIONSHIPS WITH INELIGIBLE COMPANIES

In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, course faculty, IAS–USA Board members, Viral Hepatitis Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with ineligible companies (formerly commercial interests) within the previous 24 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity. The **ACCME defines ineligible companies** as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.” Below are the financial interests that faculty members of this course have had within the past 24 months as of the date listed. View the [Faculty Financial Disclosure Policy](#).

PREPARING FOR PREP: FROM POLICY TO IMPLEMENTATION – NOVEMBER 19, 2021

Course Presenters	
Susan P. Buchbinder, MD Director, Bridge HIV San Francisco Department of Public Health Clinical Professor of Medicine and Epidemiology University of California San Francisco San Francisco, California	Dr Buchbinder has no relevant financial relationships with ineligible companies to declare. (Updated 11/16/2021)
Jeffrey S. Crowley, MPH Program Director of Infectious Disease Initiatives O'Neill Institute for National and Global Health Law Adjunct Professor of Law Georgetown University Law Center Washington, DC	Mr Crowley has received research grants paid to him through his institution from Gilead Sciences, Inc., Merck & Co, Inc., and ViiV Healthcare. He has served on advisory boards for Gilead Sciences, Inc., and Merck & Co, Inc. (Updated 11/16/21)
Monica Gandhi, MD, MPH Professor of Medicine Associate Division Chief of the Division of HIV, Infectious Diseases, and Global Medicine University of California San Francisco	Dr Gandhi has no relevant financial relationships with ineligible companies to disclose. (Updated 11/16/21)
Marina Klein, MD Professor of Medicine McGill University Montreal, Canada	Dr Klein has served as a consultant to and has received grants paid to her institution from ViiV Healthcare, AbbVie, Gilead Sciences, Inc. (Updated 11/16/21)
Raphael J. Landovitz, MD Professor of Medicine Division of Infectious Diseases David Geffen School of Medicine at UCLA Associate Director, UCLA Center for Clinical AIDS Research & Education University of California Los Angeles	Dr Landovitz has served on scientific advisory boards for Gilead Sciences, Inc., and Merck & Co, Inc. (Updated 11/16/21)
Henry Masur, MD Clinical Professor of Medicine George Washington University School of Medicine Washington, DC	Dr Masur has no relevant financial relationships with ineligible companies to declare. (Updated 11/16/21)
Jean-Michel Molina, MD Professor of Infectious Diseases University of Paris Head of the Infectious Diseases Department Saint-Louis Hospital and Lariboisière Hospital Paris, France	Dr Molina has received grant support paid to his institution from Gilead Sciences, Inc., and served as a consultant to Merck & Co, Inc., Gilead Sciences, Inc., ViiV Healthcare, Bristol-Myers Squibb, Janssen Therapeutics, and Teva. (Updated 11/16/21)
Michael S. Saag, MD Professor of Medicine Jim Straley Chair in AIDS Research Director, Center for AIDS Research Associate Dean for Global Health, School of Medicine University of Alabama at Birmingham	Dr Saag has received research grants and support awarded to his institution from Gilead Sciences, Inc., and ViiV Healthcare. (Updated 11/16/21)

Hyman Scott, MD, MPH Assistant Clinical Professor, School of Medicine University of California San Francisco	Dr Scott has no relevant financial relationships with ineligible companies to disclose. (Updated 11/16/21)
--	--

IAS–USA CME Planners and Reviewers	
Susan P. Buchbinder, MD	Dr Buchbinder has no relevant financial relationships with ineligible companies to declare. (Updated 11/16/21)
Monica Gandhi, MD, MPH	Dr Gandhi has no relevant financial relationships with ineligible companies to disclose. (Updated 11/16/21)
Henry Masur, MD	Dr Masur has no relevant financial relationships with ineligible companies to declare. (Updated 11/16/21)
Michael S. Saag, MD	Dr Saag has received research grants and support awarded to his institution from Gilead Sciences, Inc., and ViiV Healthcare. (Updated 11/16/21)
Donna M. Jacobsen Executive Director/President IAS–USA	Ms Jacobsen has no relevant financial affiliations to disclose. (Updated 11/16/21)

IAS–USA Board of Directors	
*The nonstaff members of the IAS–USA Board of Directors are not compensated for their roles in governing and overseeing the IAS–USA. Please see https://iasusa.org/about/ias-usa-board-of-directors/ for information about board members and a link to up-to-date financial disclosure information.	